返回搜索

Biosynthesis of E-series 18(R)-resolvins

Reactome ID: R-HSA-9023661

中文名称

胆汁酸和胆汁盐的合成

通路描述

在健康的成年人类中,每天约有 500 毫克的胆固醇被转化为胆汁盐(Russell 2003)。肝脏中胆汁盐合成的主要途径始于胆固醇转化为 7α-羟基胆固醇。胆汁盐合成也可始于类固醇氧化物 -24-羟基胆固醇或 27-羟基胆固醇的合成。在体内,这两种途径的初始步骤发生在额外肝外组织中,生成中间产物,随后被运输至肝脏并通过 7α-羟基胆固醇途径转化为胆汁盐。这些额外肝外途径对胆汁盐的总合成贡献很小,但被认为在胆固醇稳态中发挥重要作用(Javitt 2002)。
英文描述
Biosynthesis of E-series 18(R)-resolvins Eicosapentaenoic acid (EPA), a major ω-3 polyunsaturated fatty acid (PUFA) found in fish oil is the source of E-series resolvins, one of the specialized proresolving mediators (SPMs) that show potent anti-inflammatory and pro-resolving actions (Molfino et al. 2017, Calder 2017). The initial transformation of EPA can be mediated by either cytochrome P450s or aspirin-acetylated cyclooxygenase-2, resulting in 18(R)- and 18(S)-stereospecific E-resolvins. Combinations of oxidation, reduction and hydrolysis reactions determine the type of E-resolvin formed (RvE1, RvE2 or RvE3) (Serhan & Petasis 2011). Aspirin acetylation of cyclooxygenase isoforms results in changed activities. Acetylation of cyclooxygenase-1 results in its inhibition and thereby halting production of inflammatory mediators. However, acetylation of cyclooxygenase-2 transforms its enzyme activity from a cyclooxygenase to a lipoxygenase, thereby blocking prostaglandin biosynthesis and, additionally, initiating the production of SPMs (Arita et al. 2005, Kyriakopoulos et al. 2017). The biosynthesis of 18(R) E-resolvins is described here.

所含基因

3 个基因